|
Market Closed -
Australian S.E.
08:17:30 11/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 14.02 AUD | +1.59% |
|
+5.26% | +25.18% |
| 11-10 | Telix Pharmaceuticals Limited - Analyst/Investor Day | |
| 10-21 | Telix Pharmaceuticals Limited Reports Unaudited Revenue Results for the Third Quarter Ended September 30, 2026 | CI |
Company Valuation: Telix Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,209 | 2,300 | 3,263 | 8,238 | 3,794 | 4,689 | - | - |
| Change | - | 4.1% | 41.89% | 152.44% | -53.95% | 23.6% | - | - |
| Enterprise Value (EV) 1 | 2,187 | 2,187 | 3,149 | 8,098 | 4,167 | 5,198 | 5,113 | 5,086 |
| Change | - | -0.02% | 44.01% | 157.15% | -48.55% | 24.75% | -1.64% | -0.52% |
| P/E | -27.2x | -21.7x | 626x | 170x | -375x | 207x | 2,505x | 57.8x |
| PBR | 1,024x | 28.7x | 21.9x | 14.5x | 6.43x | 4.79x | 6.46x | 5.85x |
| PEG | - | -1.2x | -6x | 0x | 3x | -1x | -27.3x | 0x |
| Capitalization / Revenue | 291x | 14.4x | 6.49x | 10.5x | 3.17x | 3.36x | 2.96x | 2.51x |
| EV / Revenue | 288x | 13.7x | 6.27x | 10.3x | 3.48x | 3.72x | 3.22x | 2.72x |
| EV / EBITDA | -31.2x | -32.3x | 53.9x | 81.6x | 74.4x | 58.5x | 62.7x | 29.8x |
| EV / EBIT | -29.1x | -29.9x | 60.9x | 88.7x | 98.7x | 93x | 109x | 39.8x |
| EV / FCF | -35.2x | -29.9x | 223x | 282x | -68.4x | 243x | -999x | 59x |
| FCF Yield | -2.84% | -3.35% | 0.45% | 0.35% | -1.46% | 0.41% | -0.1% | 1.69% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.285 | -0.335 | 0.0161 | 0.1446 | -0.0299 | 0.0666 | 0.00551 | 0.2386 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7.596 | 160.1 | 502.5 | 783.2 | 1,198 | 1,396 | 1,587 | 1,869 |
| EBITDA 1 | -70.07 | -67.8 | 58.44 | 99.28 | 55.98 | 88.82 | 81.52 | 170.9 |
| EBIT 1 | -75.25 | -73.18 | 51.69 | 91.26 | 42.23 | 55.87 | 46.71 | 127.7 |
| Net income 1 | -80.51 | -104.1 | 5.211 | 49.92 | -10.1 | 27.03 | 2.507 | 81.53 |
| Net Debt 1 | -22.02 | -113 | -114.1 | -139.5 | 372.9 | 508.8 | 423.8 | 396.9 |
| Reference price 2 | 7.75 | 7.27 | 10.08 | 24.61 | 11.20 | 13.80 | 13.80 | 13.80 |
| Nbr of stocks (in thousands) | 285,073 | 316,343 | 323,727 | 334,724 | 338,721 | 339,784 | - | - |
| Announcement Date | 2/23/22 A | 2/27/23 A | 2/22/24 A | 2/20/25 A | 2/19/26 A | - | - | - |
1AUD in Million2AUD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 207.15x | 3.72x | 58.52x | -.--% | 3.21B | |
| 17.83x | 6.86x | 13.15x | 1.67% | 68.32B | |
| 32.59x | 8.71x | 28.8x | 0.07% | 60.26B | |
| 38.31x | 6.82x | 20.38x | 0.85% | 55.86B | |
| 47.19x | 6.4x | 30.36x | -.--% | 48.43B | |
| 35.91x | 3.38x | 14.61x | -.--% | 45.34B | |
| -23.04x | 61.61x | -25.45x | -.--% | 41.76B | |
| 34.38x | 8.51x | 22.17x | 0.38% | 34.5B | |
| 41.76x | 8.19x | 27.2x | -.--% | 33.8B | |
| 30.01x | 6.36x | 16.49x | -.--% | 25.96B | |
| Average | 46.21x | 12.06x | 20.62x | 0.3% | 42B | |
| Weighted average by Cap. | 29.50x | 12.36x | 17.11x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- TLX Stock
- Valuation Telix Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
